e-learning
resources
Virtual 2020
Pre-Congress Content
Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD).
F. Bonella (Essen, Germany), H. Balasz (Essen, Germany), E. Gottstein (Essen, Germany), D. Theegarten (Essen, Germany), U. Costabel (Essen, Germany), C. Taube (Essen, Germany)
Source:
Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Session:
Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Session type:
E-poster session
Number:
801
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Bonella (Essen, Germany), H. Balasz (Essen, Germany), E. Gottstein (Essen, Germany), D. Theegarten (Essen, Germany), U. Costabel (Essen, Germany), C. Taube (Essen, Germany). The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD).. 801
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study.
Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes
Year: 2021
Diagnostic value of induced sputum (IS) in interstitial lung disease (ILD)
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 106s
Year: 2002
Safety of sputum induction (SI) in interstitial lung disease (ILD)
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Prognostic factors of interstitial lung disease (ILD)
Source: Eur Respir J 2001; 18: Suppl. 33, 527s
Year: 2001
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
The composite physiological index strongly predicts mortality in interstitial lung disease (ILD) associated pulmonary hypertension (PH-ILD)
Source: International Congress 2017 – Imaging and lung disease PH
Year: 2017
TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001
KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013
Red cell distribution width (RDW) as a biomarker of disease severity in ILD patients
Source: International Congress 2015 – Acute and chronic lung diseases: good clinical practice
Year: 2015
Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
A neo-epitope of collagen type VII (C7) is elevated in serum of patients with COPD and SSC
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
Diagnostic value of CD4/CD8 ratio in induced sputum (IS) in interstitial lung disease (ILD)
Source: Annual Congress 2004 - Pathobiological and clinical investigations in interstitial lung diseases
Year: 2004
Telomere (TL) shortening is associated with disease severity in scleroderma (SSC) associated interstitial lung disease (ILD)
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
Total lung capacity (TLC) or vital capacity (VC) - which is more reduced in interstitial lung disease (ILD) patients?
Source: Eur Respir J 2001; 18: Suppl. 33, 150s
Year: 2001
Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD)
Source: International Congress 2015 – Connective tissue disorders
Year: 2015
Plasma level of total hydroperoxide (TH) as a marker of oxidative stress seems to be a useful index of disease severity in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept